LUMIRABIO at CPHI China 2026: Peptide API Conversations and Next Steps

CPHI China 2026 at a glance

The 24th CPHI China and 19th PMEC China took place at the Shanghai New International Expo Centre from 16 to 18 June 2026.

The organizer's post-event report recorded 250,000 square metres of exhibition space, 3,701 exhibiting companies and 129,172 professional visits from 168 countries and regions.

These are organizer-reported event figures.

The exhibition covered pharmaceutical ingredients, biotechnology, contract services, formulations, process equipment, analytical tools and other parts of the pharmaceutical value chain.

Peptides appeared not only as product programs, but also in discussions around synthesis, purification, analytical control, formulation, scale-up and international regulatory requirements.

That breadth matters because a peptide API decision is rarely made by procurement alone.

Discovery, CMC, analytical, quality, regulatory, legal and supply-chain teams all bring different questions to the same project.

Why semaglutide, tirzepatide and retatrutide drew attention

Our display and discussions included semaglutide-, tirzepatide- and retatrutide-related programs.

Interest reflects the expansion of incretin-based medicines and continued research into multi-receptor peptide candidates.

Novo Nordisk's 2025 annual report recorded net sales of DKK 127.1 billion for Ozempic, DKK 79.1 billion for Wegovy and DKK 22.1 billion for Rybelsus, three finished medicinal products based on semaglutide.

Lilly reported 2025 worldwide revenue of USD 22.965 billion for Mounjaro and USD 13.542 billion for Zepbound, both tirzepatide brands.

These figures describe branded finished-product sales, not merchant API demand or eligibility of a third-party material source.

Retatrutide remains an investigational molecule in Phase 3 development.

It must not be presented as an approved medicine or an approved drug component.

Its status, intended use and target-market eligibility are reviewed separately from approved semaglutide- and tirzepatide-based finished medicines.

What LUMIRABIO presented in Shanghai

LUMIRABIO has established a peptide technical platform covering R&D assessment, synthesis, purification, lyophilization and quality testing.

At CPHI China 2026, we used semaglutide, tirzepatide and retatrutide programs to make that platform concrete rather than presenting capability only in general terms.

Our technical focus included route and modification review, target purity, related-peptide control, purification strategy, final-form considerations, identity testing, chromatographic purity and project-specific documentation.

We support feasibility discussions from research and process development through pilot, scale-up and qualified supply planning.

High purity, impurity control, batch consistency and reliable supply are managed against the applicable specification, method, batch record, production plan and destination requirements.

The formal offer identifies the relevant site, entity, quantity, documents and market pathway.

What global pharmaceutical and procurement teams asked us

During the three-day event, our team met pharmaceutical companies, API procurement teams and contract research or development organizations from Europe, the Americas, Southeast Asia, the Middle East, Japan, Korea and other markets.

Conversations covered product parameters, quality standards, impurity profiles, capacity and delivery planning, customized development and cross-border cooperation.

The recurring questions concerned material form and specification, identity and purity methods, intended use, quantity and batch schedule, packaging and storage, site and quality-system evidence, destination-market pathways and intellectual-property constraints.

Our original Chinese event recap reported multiple preliminary cooperation intentions.

The event generated company-reported follow-up opportunities that now move through technical, quality and commercial qualification.

• What form, counter-ion and specification is required?
• Which methods support identity, purity and related-peptide assessment?
• Is the project for research, development, registration work or another permitted use?
• What quantity, batch schedule, packaging and storage conditions apply?
• Which site, quality-system evidence and target-market requirements govern?

Why every peptide API inquiry needs a project-specific review

A peptide name does not define a complete requirement.

The same parent sequence may be requested in different forms, counter-ions, purity grades, quantities, packaging configurations or analytical-document scopes.

Intended use and destination can also change the legal and regulatory pathway.

Process understanding matters because peptide-related impurities can arise from incomplete coupling, deletion sequences, epimerization, oxidation, deamidation, conjugation or handling.

ICH Q11 notes that for peptides synthesized on a solid support, the relationship between remaining process steps and impurity-purge risk can differ from conventional small-molecule synthesis.

A useful review connects molecule identity, intended use, synthesis and purification route, specification, analytical methods, batch evidence, site and scale, packaging, storage, delivery, regulatory status and intellectual-property eligibility.

From an exhibition conversation to a documented project review

The next step after CPHI is a structured technical intake.

Teams should provide the peptide name or CAS number, requested form, target specification, quantity, program stage, intended use, destination market, required documents, packaging preference and target timeline.

LUMIRABIO then connects the inquiry to route assessment, synthesis and purification planning, lyophilization or final-form considerations, analytical review, batch-document alignment, capacity and supply planning.

This turns market interest into a reviewable B2B project rather than a generic catalogue request.